Summary of Key Issues
A severe shortage of the classic anti-cancer drug cyclophosphamide has recently occurred in many regions across the country, with patients seeking the medication across provinces and hospitals facing urgent stock shortages. The direct cause of the shortage is a technical failure at the factory producing the imported original drug. Although several domestic companies have approval to produce generic versions, they are reluctant to continue supplying due to meager profits, leading to a disruption in the supply chain. This shortage of this "universal drug" used in various departments such as oncology and hematology highlights the common dilemma faced by low-cost, classic medications: patients rely on them, but companies cannot make a profit.
I. The Immediate Trigger for the Shortage: Sudden Disruption in Import Supply
The imported original version of cyclophosphamide, "Adriamycin," is produced by Baxter Healthcare. However, in February this year, Baxter informed Caiseng Pharmaceutical (the Chinese distributor) that the manufacturing plant, which was responsible for production, had a technical failure, resulting in an interruption in both production and product release, with supplies expected to be tight for the next nine months. Worse still, the US FDA issued a warning letter to the factory in March, identifying systemic issues with sterile production (such as harmful bacteria detected 47 times during environmental monitoring), requiring a shutdown for rectification that could last at least six months to a year. This means that imported supplies will not be available for a significant period, directly cutting off one of the market sources.
II. Why Don't Domestic Generics Meet the Demand Despite Having Approval?
Several Chinese companies, including Hengrui and Huiyu, have approval to produce generic cyclophosphamide. In fact, Hengrui even passed the "consistency evaluation" in 2021, ensuring that its product meets quality standards equivalent to the original drug. However, only a few companies are actually providing stable supplies. The main reasons are economic:
- Low prices: As a Class A medication covered by medical insurance and part of the national essential drug list, the listed price for cyclophosphamide is only 23 yuan per vial, leaving very little profit margin.
- Small market size: Sales in Chinese urban public hospitals in 2023 were only 203 million yuan, and globally, they amounted to 1.9 billion yuan. Such a small market cannot support multiple companies.
- Company focus on higher-profiting drugs: Companies like Hengrui prioritize the development of more profitable innovative medications, making cyclophosphamide a less attractive product with minimal contribution to overall sales.
III. How Important Is This Old Drug?
Cyclophosphamide, introduced in 1959, remains an essential "cornerstone drug" in clinical practice:
- Cancer treatment: It is used in two classic chemotherapy regimens for breast cancer and is a key component of the first-line regimen R-CHOP for lymphoma. It is also necessary for CAR-T therapy to eliminate lymphocytes from patients' bodies.
- Autoimmune diseases: It serves as a crucial immunosuppressive agent for serious conditions such as systemic lupus erythematosus and vasculitis.
- Cross-departmental use: It is indispensable in oncology, hematology, rheumatology, and transplantation departments.
In short, a shortage of cyclophosphamide would force adjustments to chemotherapy regimens for many cancer patients and could lead to uncontrollable conditions for those with autoimmune diseases, potentially even preventing CAR-T therapy from being administered.
IV. The Industry's Pain Points Revealed by the Shortage
The cyclophosphamide shortage is not an isolated incident but reflects a common issue for low-cost, classic medications:
- Patients depend on them, but companies cannot make a profit: There is ongoing clinical demand, but prices are suppressed by medical insurance and policy regulations, leaving companies with no incentive to produce.
- Insufficient regulatory measures: Although cyclophosphamide was included in the "Key Monitoring List for Clinically Shortage Drugs" in 2020, no mandatory policies (such as designated production or price subsidies) were implemented to ensure supply, allowing the problem to accumulate until it erupted.
- Vulnerable supply chain: Over-reliance on imports or a few companies means that a disruption in one link can cause a nationwide shortage.
V. Current Emergency Measures and Long-Term Concerns
Some regions have already initiated emergency measures to ensure the supply of domestic generic drugs, and clinicians are experimenting with alternative oral and intravenous medications as temporary solutions. However, these only address the symptoms, not the root cause:
- Alternative drugs may not have the same efficacy as cyclophosphamide, potentially affecting treatment outcomes.
- If the issue of low profits for low-cost drugs is not resolved, similar shortages could occur with other classic medications (such as nitroglycerin and protamine).
A comprehensive solution may require policy intervention, such as providing subsidies to companies that produce these drugs, implementing designated production, allowing for reasonable price increases, or establishing national stockpiles to ensure availability in critical times. Otherwise, the cycle of "drug shortages" will continue.
In summary: The cyclophosphamide shortage is a microcosm of the survival crisis faced by low-cost, classic medications. Patients need these drugs for life-saving treatments, but companies lack the motivation to produce them due to financial constraints. This reflects a conflict between medical needs and market dynamics that requires policy intervention to balance.